Found 107 clinical trials
AHEP0731: Combination Chemotherapy in Treating Young Patients with Newly Diagnosed Liver Cancer
AHEP0731: Combination Chemotherapy in Treating Young Patients with Newly Diagnosed Liver Cancer
- 437 views
- 07 Nov, 2020
- 1 location
AALL0434: Combination Chemotherapy in Treating Young Patients with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia
AALL0434: Combination Chemotherapy in Treating Young Patients with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia
- 171 views
- 08 Nov, 2020
- 1 location
The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer
Pancreatic cancer represents the most lethal of the common malignancies with a 5-year survival rate of less than 5%. For patients who are eligible for potentially curative resection, despite mortality and morbidity rates after surgery have improved, the recurrence rate is up to 85% within 2 years. FOLFIRINOX (fluoropyrimidine/leucovorin plus …
- 16 views
- 26 Feb, 2022
- 2 locations
Pancreatic Adenocarcinoma Neoadjuvant Combination Chemotherapy and Stereotactic Body Radiation Therapy Before Surgery
This is a single-arm, single-center feasibility trial of patients with borderline resectable pancreatic adenocarcinoma receiving radiation therapy with Stereotactic body radiation therapy (SBRT) and chemotherapy with mFOLFIRINOX or gemcitabine / nab-paclitaxel followed by pancreatectomy.
- 0 views
- 18 Sep, 2021
- 1 location
Etoposide and Cisplatin in Treating Young Patients With Previously Untreated High-Risk Neuroblastoma Undergoing High-Dose Chemotherapy Stem Cell Transplant and Isotretinoin
(combination chemotherapy) and giving them in different doses may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Peripheral blood stem cell transplant using
- 24 views
- 07 Nov, 2020
- 1 location
Neoadjuvant Therapy Followed by Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Pancreatic Cancer
The purpose of this study is to evaluate a new treatment routine for patients with borderline resectable and unresectable pancreas cancers.
- 9 views
- 08 Nov, 2020
- 1 location
PAXG Out in the Country
The objective of this study is to assess the reproducibility of PAXG regimen as first-line/primary chemotherapy in daily clinical practice in Pancreatic Ductal Adenocarcinoma (PDAC) borderline resectable, locally advanced or metastatic patients out of a large volume center.
- 0 views
- 19 Feb, 2021
- 30 locations
Preoperative CRT With Capecitabine Temozolomide in Patients With LARC
This is a prospective biomarker-stratified, randomised phase II study of preoperative CRT with temozolomide plus capecitabine in patients with locally advanced rectal cancer. The primary endpoint is pathologic complete response rates defined as total regression of the primary tumor. For each cohort of MGMT hypermethylated versus MGMT unmethylated, patients will …
- 26 views
- 27 Jan, 2021
- 1 location
Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy
Gestational trophoblastic Neoplasia（GTN） is a kind of malignant tumor in women of childbearing age. It is easy to metastasized through the blood system in the early stage, so it is a relatively malignant tumor. The tumor is highly sensitive to chemotherapy, and low-risk patients have good prognosis, with survival rate …
- 0 views
- 30 Dec, 2021
- 1 location
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
This randomized phase III trial studies how well standard-dose combination chemotherapy works compared to high-dose combination chemotherapy and stem cell transplant in treating patients with
- 907 views
- 03 May, 2022
- 103 locations